CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. HOOD
9. ABBV
10. DFTX

Go back to CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino

CRISPR Therapeutics (CRSP) Prices 4.25M Share Common Offering at $64.50/Sh

November 21, 2019 5:52 AM EST

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,250,000 common shares at a public offering price of $64.50 per share. In addition, the underwriters have a 30-day... More

CRISPR Therapeutics (CRSP) Announces Proposed 4.25M Common Share Offering

November 19, 2019 4:15 PM EST

CRISPR Therapeutics (NASDAQ: CRSP) today announced that it is commencing an underwritten public offering of 4,250,000 common shares. In addition, the underwriters will have a 30-day option to purchase up to 637,500 additional common shares at the public offering price less the underwriting... More

Vertex (VRTX) PT Raised to $229 at Cantor Fitzgerald

November 19, 2019 11:11 AM EST

Cantor Fitzgerald analyst Alethia Young raised the price target on Vertex (NASDAQ: VRTX) to $229.00 (from $217.00) while maintaining a Overweight rating.

... More